Memory halts study after FDA requests more data - Pharmaceutical Business Review

Memory halts study after FDA requests more data - Pharmaceutical Business Review: "Memory Pharmaceuticals has halted its phase IIa trial of MEM 3454 for Alzheimer's disease, after the FDA raised concerns over data relating to the drug."